|
|
Vaccine Detail
|
Berzofsky Ras/P53 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: Berzofsky Ras/P53 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007330
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53
- human TP53 (P53)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Patients’ peripheral-blood mononuclear cells were pulsed with mutant p53- and K-ras-derived peptides (Carbone et al., 2005).
- Description: A synthetic vaccine combining the peptide antigens of two proteins, ras oncoprotein and tumor suppressor p53. (NCI04) (NCIT_C2746). Cellular immunity to mutant p53 and K-ras oncopeptides is associated with longer survival. https://ascopubs.org/doi/10.1200/JCO.2005.03.158?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
|
| Host Response |
|
|
| References |
Carbone et al., 2005: Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, Maher VE, Stipanov M, Contois D, Johnson BE, Pendleton CD, Seifert B, Carter C, Read EJ, Greenblatt J, Top LE, Kelsey MI, Minna JD, Berzofsky JA. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005; 23(22); 5099-5107. [PubMed: 15983396].
NCIT_C2746: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2746]
|
|
